Methods and compositions for wound healing
US-2024139237-A1 · May 2, 2024 · US
Cyclopropylamines as LSD1 inhibitors
US10064854B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10064854-B2 |
| Application number | US-201715708270-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 19, 2017 |
| Priority date | Mar 25, 2011 |
| Publication date | Sep 4, 2018 |
| Grant date | Sep 4, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating a hematologic cancer which comprises administering to a human in need thereof an effective amount of a compound which is 4-((4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid, represented by the formula: or a pharmaceutically acceptable salt thereof, wherein said hematologic cancer is selected from the group consisting of: acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome, Hodgkin's disease, and non-Hodgkin's lymphoma. 2. The method of claim 1 wherein said hematologic cancer is myelodysplastic syndrome. 3. The method of claim 1 , further comprising administering an additional therapeutic agent selected from the group consisting of tretinoin, azacitidine, and decitabine. 4. The method of claim 3 , wherein said additional therapeutic agent is tretinoin. 5. The method of claim 3 , wherein said additional therapeutic agent is azacitidine. 6. The method of claim 3 , wherein said additional therapeutic agent is decitabine. 7. The method of claim 3 , wherein said hematologic cancer is myelodysplastic syndrome. 8. The method of claim 4 , wherein said hematologic cancer is myelodysplastic syndrome. 9. The method of claim 5 , wherein said hematologic cancer is myelodysplastic syndrome. 10. The method of claim 6 , wherein said hematologic cancer is myelodysplastic syndrome. 11. The method of claim 3 , wherein said hematologic cancer is acute myeloid leukemia. 12. The method of claim 4 , wherein said hematologic cancer is acute myeloid leukemia. 13. The method of claim 5 , wherein said hematologic cancer is acute myeloid leukemia. 14. The method of claim 6 , wherein said hematologic cancer is acute myeloid leukemia.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
specific for leukemia · CPC title
containing at least two amino groups bound to the carbon skeleton · CPC title
Boron compounds · CPC title
The ring being saturated · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10064854B2 cover?
- This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
- Who is the assignee on this patent?
- Glaxosmithkline Ip No 2 Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/445. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).